Gilead Sciences, Inc. $GILD Shares Sold by Ilmarinen Mutual Pension Insurance Co

Key Points

• Ilmarinen Mutual Pension Insurance Co cut its Gilead Sciences stake by 8.3% in the fourth quarter, selling 18,000 shares and leaving it with 198,000 shares worth about $24.3 million.
• Gilead insiders have been selling shares, including Johanna Mercier and CEO Daniel Patrick O’Day, with 53,000 shares sold over the last three months under pre-arranged 10b5-1 plans.
• Analysts remain bullish on Gilead, with multiple firms raising price targets and the stock carrying a “Moderate Buy” consensus; the company also beat Q1 earnings and revenue estimates and declared a quarterly dividend of $0.82 per share.

Ilmarinen Mutual Pension Insurance Co reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,000 shares of the biopharmaceutical company's stock after selling 18,000 shares during the period. Ilmarinen Mutual Pension Insurance Co's holdings in Gilead Sciences were worth $24,303,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GILD. Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Financial Consulate Inc. boosted its holdings in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 109 shares during the period. North Star Investment Management Corp. boosted its holdings in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 86 shares during the period. BOCHK Asset Management Ltd acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $31,000. Finally, MTM Investment Management LLC boosted its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 176 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a "buy" rating in a report on Monday, April 13th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Wednesday, February 11th. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, February 11th. Finally, Weiss Ratings upgraded Gilead Sciences from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $156.93.

Gilead Sciences Trading Up 1.9%

Gilead Sciences stock opened at $136.22 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $135.43 and a two-hundred day moving average price of $134.08. The firm has a market capitalization of $169.13 billion, a price-to-earnings ratio of 18.56 and a beta of 0.31. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences's revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences's payout ratio is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.